What is SLNCF's health score?

Silence Therapeutics plc (SLNCF) has a TradeApes health score of 38 out of 100, rated Weak. This composite score evaluates financial strength, operating trends, valuation, capital allocation, and risk factors.

What is SLNCF's estimated fair value?

Based on our 5-year discounted cash flow model, Silence Therapeutics plc's estimated fair value is $N/A per share. This is a model estimate, not a price target or investment recommendation.

Is SLNCF undervalued or overvalued?

Our model currently rates SLNCF as Fair Value. This assessment combines health metrics, valuation multiples, and market sentiment. Individual investors should conduct their own due diligence.

Crunching the numbers for SLNCF... Refresh in a moment for the full analysis.

Silence Therapeutics plc (SLNCF)

Healthcare Fair Value High weak

Updated: 2026-04-21

TradeApes Score

reduce

Financial Strength

50 Mixed

Operating Trend

28 Stressed

Relative Value

40 Weak

Capital Allocation

25 Stressed

Risk

50 Mixed

Key Findings

+ Low leverage — net debt/EBITDA below 1×

Unlock Full Report →

− Sharp revenue decline — sales down more than 15% year over year

Unlock Full Report →

3 free score cards remaining

TradeApes provides financial data, analytics, and research tools. TradeApes is not a registered investment adviser, broker-dealer, or tax advisor. The information presented is for educational and informational purposes only and does not constitute investment, financial, or tax advice.

11 sector-leading stocks delivered to your inbox every Sunday. Free.

No spam. Unsubscribe anytime.